MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.39
-0.82
-6.21%
After Hours: 12.39 0 0.00% 16:00 04/01 EDT
OPEN
12.73
PREV CLOSE
13.21
HIGH
12.88
LOW
12.28
VOLUME
346.99K
TURNOVER
--
52 WEEK HIGH
27.55
52 WEEK LOW
8.88
MARKET CAP
578.93M
P/E (TTM)
-4.9923
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CARA stock price target is 30.89 with a high estimate of 39.00 and a low estimate of 18.00.

EPS

CARA News

More
  • Cannabis Stock Gainers And Losers From March 30, 2020
  • Benzinga · 1d ago
  • Top Marijuana Stocks on the NASDAQ for April 2020
  • Investopedia · 6d ago
  • Cara Therapeutics Reports Clinical Updates
  • GlobeNewswire · 03/25 12:00
  • Covid-19-related activity - healthcare
  • Seeking Alpha - Article · 03/25 11:37

Industry

Biotechnology & Medical Research
-4.51%
Pharmaceuticals & Medical Research
-2.97%

Hot Stocks

Symbol
Price
%Change

About CARA

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
More

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.